The CB2R agonist JWH015 (Ki=13.8 nM for CB2R) increased the survival rate of mESCs at 2 × 10− 7 M with a higher potency when compared to a non-specific agonist WIN 55212-2 (Ki=3.3 nM for CB2R, Ki= 62.3 nM for CB1R) at 10− 8 M along with the induction of EB formation [18] which was attributed to the higher expression of CB2R by mESCs compared to CB1R [18]. The gene discussed is CNR1; the disease is epidermolysis bullosa.